Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-arm, Open-label, Phase 1 Trial to Evaluate the Safety and Tolerability, Pharmacokinetics and Anti-tumour Activity of MST-0312 When Given Alone and in Combination With Anticancer Treatments in Subjects With Solid Malignancies

Next Previous
Trial Profile

A Multi-arm, Open-label, Phase 1 Trial to Evaluate the Safety and Tolerability, Pharmacokinetics and Anti-tumour Activity of MST-0312 When Given Alone and in Combination With Anticancer Treatments in Subjects With Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MST 0312 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Colorectal cancer; Gastrointestinal cancer; Multiple myeloma; Non-small cell lung cancer; Skin cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms MST-0312-1001; STARLYS
  • Sponsors Mestag Therapeutics

Most Recent Events

  • 28 May 2026 Planned number of patients changed from 42 to 157.
  • 28 May 2026 Status changed from not yet recruiting to recruiting.
  • 28 May 2026 Planned End Date changed from 31 Dec 2026 to 31 Dec 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top